No Data
No Data
FineIndex --- Medical System Implementation and Sales Results as of 2024/5/1 (latest)
On the 20th, Finex <3649> announced medical system implementation and sales results (latest) as of 2024/5/1. The number of major products introduced is the image filing system Claio (of which 438 are hospital ophthalmology solutions), 884 cases of the electronic medical record REMORA, 79 cases of the perinatal system MapleNote, 660 cases of the document preparation system Documaker, and 173 cases of the paper/digital management document system C-Scan.
Fine Index--1Q saw a 2-digit increase in sales and a significant increase in profit, and the health care business and public business showed strong sales
Fine Index <3649> announced consolidated financial results for the 1st quarter (24/1/03) of the fiscal year ending 2024/12 on the 14th. Sales increased 69.7% from the same period last year to 2.124 billion yen, operating profit increased 199.0% to 862 million yen, ordinary profit increased 196.2% to 865 million yen, and quarterly net profit attributable to parent company shareholders increased 222.4% to 642 million yen. Sales in the medical business increased 69.3% from the same period last year to 1,996 billion yen, and operating profit increased 181.9%
Volume change rate ranking (9:00) ~ Finatext, Mitsui Marine, etc. rank
* In the volume change rate ranking, it is possible to know the interest of market participants, such as shopping trends, by comparing the average turnover for the last 5 days with the turnover on the day of distribution. ■Top Volume Change Rate [5/15 9:35 as of 9:35] (Last 5 Day Average Volume Comparison) Stock Code Stock Name Volume 5 Day Average Volume Volume Change Rate Stock Price Change Rate <4078> Sakai Chemical 344000 107185.08 280.19% 0.014
Findex: Quarterly Report - 1st quarter of the 40th term (2024/01/01 - 2024/03/31)
Findex: Confirmation
Findex 1Q Net Y642.00M Vs Net Y199.00M
Findex Inc. (3649.TO) Japan 1st Quarter Ended March 31 GROUP 2024 2023 Revenue Y2.12 bln Y1.25 bln Operating Profit Y862.00 mln Y288.00 ml
No Data